CORBUS PHARMACEUTICALS HOLDINGS, - CRB-913 TREATMENT DISCONTINUATIONS DUE TO ADVERSE EVENTS RANGE FROM 3.1% TO 13.1%

Reuters · 3d ago

Please log in to view news